Initial Real-Life Experience from a Designated COVID-19 Centre in Athens, Greece: a Proposed Therapeutic Algorithm
Abstract We report our initial experience with the management of a mixed group of patients with COVID-19 infection, admitted and treated in a designated COVID-19 centre in the Athens Metropolitan area over a 4-week period. The SARS-CoV-2 pandemic presented a huge challenge to the Greek National Healthcare System and healthcare workers. Their response so far has been miraculously effective. Since there are essentially no therapeutic guidelines yet for this disease, we relied mainly on our medical intuition, our empathy for our patients and team work to do the best possible for 49 people with this infection. We present the therapeutic algorithm we gradually developed (on the job) and applied in our patients, based on continuous creative brainstorming and monitoring of the literature..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 2(2020), 6 vom: 26. Mai, Seite 689-693 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baraboutis, Ioannis G. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| doi: |
10.1007/s42399-020-00324-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR040131912 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040131912 | ||
| 003 | DE-627 | ||
| 005 | 20230519104352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-020-00324-x |2 doi | |
| 035 | |a (DE-627)SPR040131912 | ||
| 035 | |a (SPR)s42399-020-00324-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Baraboutis, Ioannis G. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Initial Real-Life Experience from a Designated COVID-19 Centre in Athens, Greece: a Proposed Therapeutic Algorithm |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract We report our initial experience with the management of a mixed group of patients with COVID-19 infection, admitted and treated in a designated COVID-19 centre in the Athens Metropolitan area over a 4-week period. The SARS-CoV-2 pandemic presented a huge challenge to the Greek National Healthcare System and healthcare workers. Their response so far has been miraculously effective. Since there are essentially no therapeutic guidelines yet for this disease, we relied mainly on our medical intuition, our empathy for our patients and team work to do the best possible for 49 people with this infection. We present the therapeutic algorithm we gradually developed (on the job) and applied in our patients, based on continuous creative brainstorming and monitoring of the literature. | ||
| 650 | 4 | |a COVID-19 infection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coinfections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bovine coronavirus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ferritin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a C-reactive protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a D-dimer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Viral replication |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Human immunodeficiency virus (HIV) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pneumocystis jiroveci pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oral candidiasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adult respiratory distress syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytokine release syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunomodulatory therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interleukin-6 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interleukin-1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Soluble urokinase-type plasminogen activator receptor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antimicrobial therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Corticosteroids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lung microbiota |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Gargalianos, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Aggelonidou, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Adraktas, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d [Cham] : Springer International Publishing, 2019 |g 2(2020), 6 vom: 26. Mai, Seite 689-693 |w (DE-627)SPR038535785 |w (DE-600)2947252-0 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2020 |g number:6 |g day:26 |g month:05 |g pages:689-693 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42399-020-00324-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2020 |e 6 |b 26 |c 05 |h 689-693 | ||